Health

Foresight Diagnostics to demonstrate utility of PhasED-Seq technology at ICML meeting – News-Medical.Net

Foresight Diagnostics, the emerging leader in blood-based lymphoma disease monitoring, announced today that clinical performance…

Published

4 years ago

June 18, 2021

Noosa Online News Publisher

Foresight Diagnostics, the emerging leader in blood-based lymphoma disease monitoring, announced today that clinical performance of its minimal residual disease (MRD) detection platform in diffuse large B-cell lymphoma (DLBCL) will be presented at the 16th…

Click here to view the original article.

Related Topics:Australia News-Medical.Net

Up Next

Alarming COVID study indicates long-term loss of gray matter and other brain tissue – News-Medical.Net

Don't Miss

Study finds that immune system protein may defend against deadly intestinal disease in babies – EdexLive

Noosa News23 hours ago

Death of German shepherd Arnie prompts Brisbane community action to protect pets caught up in crime

General16 hours ago

ARIA Awards 2025 winners: Amyl & The Sniffers and Ninajirachi dominate

Noosa News16 hours ago

Police officer who tracked Toyah Cordingley’s phone gives evidence at Rajwinder Singh’s murder trial

General18 hours ago

Perth man charged after investigation into organised crime and tobacco store attacks

Noosa Online News

Foresight Diagnostics to demonstrate utility of PhasED-Seq technology at ICML meeting – News-Medical.Net

Trending